IP Library › Granted Patent US 12,201,659
Granted Patent B2
US 12,201,659 · App. 16/980,359 · Granted Jan 21, 2025

Foamy viruses and methods of use

Inventors: Yasuhiro Ikeda (Rochester, MN); Karol M. Budzik (Mount Prospect, IL); Stephen James Russell (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research
A61K35/768A61P35/00C12N7/00C12N2740/17021C12N2740/17022C12N2740/17032
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,201,659
App. No.
16/980,359
Granted
Jan 21, 2025
Kind
B2
Abstract

This document provides methods and materials for treating cancer. For example, foamy viruses (e.g., simian foamy viruses) are provided as well as methods and materials for treating cancer using foamy viruses as an oncolytic agent.

Claims (8)

1. A chimeric simian foamy virus (SFV) comprising:

(a) a first genomic fragment comprising a 5′ LTR, a nucleic acid encoding a gag polypeptide, and a 5′ portion of a nucleic acid encoding a pol polypeptide of a chimpanzee PAN1 SFV strain;

(b) a second genomic fragment comprising a 3′ portion of a nucleic acid encoding a pol polypeptide, a nucleic acid encoding an env polypeptide, a nucleic acid encoding a tas polypeptide, a nucleic acid encoding a bel2 polypeptide, and a 3′ LTR of a chimpanzee PAN2 SFV strain, and

(c) a transgene.

2. The chimeric SFV of claim 1 , wherein said 5′ portion of said nucleic acid encoding said pol polypeptide and said 3′ portion of said nucleic acid encoding said pol polypeptide are separated by a SfiI restriction site.

3. The chimeric SFV of claim 1 , wherein said transgene encodes a receptor.

4. The chimeric SFV of claim 3 , wherein said receptor is a chimeric antigen receptor (CAR).

5. The chimeric SFV of claim 4 , wherein said CAR can target a cancer antigen.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2021
From: IKEDA, YASUHIRO; BUDZIK, KAROL M.; RUSSELL, STEPHEN JAMES
To: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Reel/Frame 055439/0008 →
Continuity (2)
Provisional Application 62663637 · Apr 27, 2018
Related Publication 20210046134A1 · Feb 18, 2021
References Cited (49)
US 20120087894A1 · Jolly et al. · 2012 [cited by applicant]
US 20140140962A1 · Carrico et al. · 2014 [cited by applicant]
US 20160083462A1 · Yang et al. · 2016 [cited by applicant]
US 20190055299A1 · Thokala et al. · 2019 [cited by applicant]
US 20190085081A1 · Bicknell et al. · 2019 [cited by applicant]
EP 2583974 · 2017 [cited by applicant]
WO WO2000077177 · 2000 [cited by applicant]
WO WO2015142675 · 2015 [cited by applicant]
WO WO2018027155A1 · 2018 [cited by examiner]
Liu et al. Molecular Ecology and Natural History of Simian Foamy Virus Infection in Wild-Living Chimpanzees. PLoS Pathog. 2008; 4(7): e1000097. p. 1-22. (Year: 2008). [cited by examiner]
SFV-1 pol gene restriction analysis. performed on Feb. 20, 2024. (Year: 2024). [cited by examiner]
Liu et al., PLoS Pathog. 2008; 4(7): e1000097, p. 1-22. (Year: 2008). [cited by examiner]
Meiering et al. Clinical Microbiology Reviews. 2001; 14(1): 165-176. (Year: 2001). [cited by examiner]
Bauer et al., Nature Medicine. 2008; 14(1): 93-97. (Year: 2008). [cited by examiner]
Beard et al., “Unique Integration Profiles in a Canine Model of Long-Term Repopulating Cells Transduced with Gammaretrovirus, Lentivirus, or Foamy Virus,” Hum. Gene Therapy, May 2007, 18(5):423-434. [cited by applicant]
Budzik et al., “Engineering Simian Foamy Virus for safe and effective tumoricidal therapy,” Abstract, Presented at Proceedings of the American Society for Gene and Cell Therapy Conference, Chicago, IL, May 16-19, 2018, … [cited by applicant]
Campbell et al., “Characterization of the Internal Promoter of Simian Foamy Viruses,” J. Virology, Aug. 1994, 68(8):4811-4820. [cited by applicant]
Cancer.gov [online], “Cancer Stat Facts: Cancer of Any Site,” available on or before Nov. 12, 2015 via Internet Archive: Wayback Machine. URL<https://web.archive.org/web/20051112204314/https://seer.cancer.gov/statfacts/… [cited by applicant]
Chiocca et al., “Oncolytic Viruses and Their Application to Cancer Immunotherapy,” Cancer Immunol. Research, Apr. 2014, 2(4):295-300. [cited by applicant]
Erlwein et al., “Progress and prospects: Foamy virus vectors enter a new age,” Gene Therapy, Jul. 15, 2010, 17(12):1423-1429. [cited by applicant]
GenBank Accession No. L25422.1, “Simian foamy virus type 6 long terminal repeat (LTR),” dated Jun. 5, 1995, 2 pages. [cited by applicant]
GenBank Accession No. X83297.1, “Simian foamy virus integrase gene (type 7),” dated Jul. 26, 2016, 1 page. [cited by applicant]
Goodman et al., “Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential,” J. Virology, Jan. 2018, 92(1):e01639-17, 25 pages. [cited by applicant]
Heinkelein et al., “Experimental therapy of allogeneic solid tumors induced in athymic mice with suicide gene-transducing replication-competent foamy virus vectors,” Cancer Gene Therapy, Dec. 2005, 12(12):947-953. [cited by applicant]
Herchenroder et al., “Infectious Proviral Clones of Chimpanzee Foamy Virus (SFVepz) Generated by Long PCR Reveal Close Functional Relatedness to Human Foamy Virus,” Virology, Dec. 20, 1995, 214(2):685-689. [cited by applicant]
Lambert et al., “Potent neutralizing antibodies in humans infected with zoonotic simian foamy viruses target conserved epitopes located in the dimorphic domain of the surface envelope protein,” PLoS Pathogens, Oct. 8, 2… [cited by applicant]
Lei et al., “Replication-Competent Foamy Virus Vaccine Vectors as Novel Epitope Scaffolds for Immunotherapy,” PLoS One, Sep. 23, 2015, 10(9):e0138458, 27 pages. [cited by applicant]
Lindemann et al., “Foamy Virus Biology and Its Application for Vector Development,” Viruses, May 2011, 3(5):561-585. [cited by applicant]
Maitra et al., “Reovirus: A Targeted Therapeutic—Progress And Potential,” Mol. Cancer Research, Oct. 2012, 10(12):1514-1525. [cited by applicant]
Mergia et al., “The Efficiency of Simian Foamy Virus Vector Type-1 (SFV-1) in Nondividing Cells and in Human PBLs,” Virology, Feb. 15, 2001, 280(2):243-252. [cited by applicant]
Olszko et al., “Foamy Virus Vectors for HIV Gene Therapy,” Viruses, Oct. 22, 2013, 5(10):2585-2600. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2019/027353, dated Oct. 27, 2020, 9 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2019/027353, dated Aug. 12, 2019, 15 pages. [cited by applicant]
Perez et al., “Design and Selection of Toca 511 for Clinical Use: Modified Retroviral Replicating Vector With Improved Stability and Gene Expression,” Mol. Therapy, Sep. 2012, 20(9):1689-1698. [cited by applicant]
Pesonen et al., “Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors,” Int. J. Cancer, Apr. 15, 2012, 130(8):1937-1947. [cited by applicant]
Pinto-Santini et al., “Foamy virus zoonotic infections,” Retrovirology, Dec. 2, 2017, 14(1):55, 14 pages. [cited by applicant]
Rehman et al., “Into the clinic: talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy,” J. Immunother. Cancer, Sep. 20, 2016, 4:53, 8 pages. [cited by applicant]
Rethwilm et al., “Evolution of foamy viruses: the most ancient of all retroviruses,” Viruses, Sep. 25, 2013, 5(10):2349-2374. [cited by applicant]
Richard et al., “Cocirculation of Two env Molecular Variants, of Possible Recombinant Origin, in Gorilla and Chimpanzee Simian Foamy Virus Strains from Central Africa,” J. Virology, Dec. 2015, 89(24):12480-12491. [cited by applicant]
Rua et al., “Genetic Characterization of Simian Foamy Viruses Infecting Humans,” J. Virology, Dec. 2012, 86(24):13350-13359. [cited by applicant]
Rua et al., “Origin, evolution and innate immune control of simian foamy viruses in humans,” Curr. Opin. Virology, Feb. 2015, 10:47-55. [cited by applicant]
Rua et al., “Viral Latency in Blood and Saliva of Simian Foamy Virus-Infected Humans,” PLoS One, Oct. 8, 2013, 8(10):e77072, 9 pages. [cited by applicant]
Russell et al., “Oncolytic Virotherapy: A Contest between Apples and Oranges,” Mol. Therapy, May 3, 2017, 25(5):1107-1116. [cited by applicant]
Russell et al., “Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy,” Mayo Clin. Proceedings, Jul. 2014, 89(7):926-933. [cited by applicant]
Tocagen.com [online], “Our Products: TOCA 511 and TOCA FC,” dated Dec. 9, 2019, available on or before Feb. 22, 2016, via Internet Archive: Wayback Machine URL<https://web.archive.org/web/20160222174403/https://tocagen.… [cited by applicant]
Budzik et al., “Oncolytic Foamy Virus: Generation and Properties of a Nonpathogenic Replicating Retroviral Vector System That Targets Chronically Proliferating Cancer Cells,” J. Virology, Mar. 10, 2021, 95(10):e00015-21… [cited by applicant]
Galvin et al., “Identification of Recombination in the Envelope Gene of Simian Foamy Virus Serotype 2 Isolated from Macaca cyclopis,” J. Virology, Aug. 2013, 87(15):8792-8797. [cited by applicant]
Hatama et al., “Isolation and sequencing of infectious clones of feline foamy virus and a human/feline foamy virus Env chimera,” J. Gen. Virology, Dec. 2001, 82(12):2999-3004. [cited by applicant]
Jia et al., “Novel microRNA Engineered Oncolytic Virotherapy for Clinical Trial,” Abstract, Presented at Proceedings of the American Society for Gene and Cell Therapy Conference, Chicago, IL, May 16-19, 2018, No. 759. [cited by applicant]